Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 05, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary Shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share allocations and does not contain financial performance data.
Material Changes
The material change reported is the provisional allocation of share awards to Non-Executive Directors for the service period of April 1, 2006, to June 30, 2006. Additionally, a prior allocation for Mr. Tom de Swaan covering January 1, 2006, to March 31, 2006, was noted. The specific allocations are as follows:
- Sir Christopher Gent: 1,674.85 Ordinary Shares
- Mr Lawrence Culp: 663.01 ADSs
- Sir Crispin Davis: 1,339.88 Ordinary Shares
- Sir Deryck Maughan: 663.01 ADSs
- Sir Ian Prosser: 753.68 Ordinary Shares
- Dr Ronaldo Schmitz: 736.94 ADSs
- Mr Tom de Swaan: 251.23 Ordinary Shares (plus 249.06 Ordinary Shares for the Jan-Mar period)
- Sir Robert Wilson: 418.71 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the final vesting status of the provisional share allocations listed for Non-Executive Directors.
- Confirm the total number of shares and ADSs held by each director following these allocations.
- Review the specific terms of the share allocation arrangements for Non-Executive Directors for the 2006 service period.